A Dual‑Action Precision System for Safer, Smarter Oncology

BioNxt’s targeted chemotherapy platform is designed to transform the way cytotoxic drugs are administered, by delivering active compounds directly into tumor tissue while minimizing exposure to healthy cells. This two-pronged mechanism concentrates drug activity where it’s needed most and rapidly neutralizes free drug outside the target area.

The result: greater potency at the tumor site, reduced systemic toxicity, and the ability to repurpose existing chemotherapy agents once considered too harmful for conventional use.

Compatible with over 100 established cytotoxic drugs, the platform supports smarter, safer, and more efficient approaches to cancer treatment.

Market Opportunity

The chemotherapy market remains a cornerstone of oncology treatment and presents significant opportunities for innovation in delivery systems:

  • The global chemotherapy drug market is projected to grow from USD 42.8 billion in 2023 to USD 63.5 billion by 2032, at a CAGR of 4.6%
    (Precedence Research, 2024).
  •  The targeted drug delivery market is expected to grow from USD 10.5 billion in 2024 to USD 28 billion by 2032, with a CAGR of 12.7%
    (Market.us, 2024).
  • The novel drug delivery systems market for cancer was valued at USD 16.8 billion in 2023, forecast to grow at a CAGR of 7.5% through 2030
    (Precedence Research, 2023).

Traditional chemotherapy still accounts for 37% of oncology prescriptions in the U.S.

(IQVIA, 2023). BioNxt’s platform addresses this enduring global demand with a novel, precision-based solution.

how it works

How It Works

  1. Localized Activation
    The system delivers cytotoxic agents that become therapeutically active primarily within the tumor microenvironment. This allows for high local drug concentrations with minimal damage to surrounding tissues.
  2. Rapid Neutralization
    Any drug that escapes the tumor zone is rapidly neutralized in peripheral tissues, greatly reducing the risk of systemic toxicity and side effects.
  3. Broad Compatibility
    The platform is designed to support a wide range of existing chemotherapy agents, including alkylating agents, topoisomerase inhibitors, and others—enabling rapid deployment and repurposing.

Strategic Advantages

  • Unlocks Existing Assets
    Revives shelved or underused cytotoxic compounds by improving safety and tolerability.
  • Partner-Ready Platform
    Ideal for generic manufacturers, specialty pharma, and biotech partners looking to enhance existing oncology pipelines.
  • Streamlined Development
    Broad drug compatibility and controlled localization reduce formulation complexity and accelerate time to clinical validation.
samuel ramos RXVfrhCswCQ unsplash

Development Status

The platform is currently in advanced preclinical development. Early in vitro data show up to 10 times greater potency within tumor models, with significantly reduced impact on healthy tissue.

The next stages include:

  • Pharmacokinetic and toxicology validation
  • Candidate selection and formulation optimization
  • First-in-human readiness targeting high-incidence solid tumors

 

Partner With Us

We are actively seeking partnerships with oncology-focused companies to co-develop therapies using this platform. Whether you’re looking to differentiate a generic asset or revive a high-potential cytotoxic compound, our technology offers a new path to precision cancer care.
Get in Touch
Scientist looking in magnifying glass XPhyto
Scientist looking in magnifying glass XPhyto

Be in the know. Get our press releases and latest news first.

Hear about our latest research, products, exclusive partnerships & more.

Unsubscribe anytime. View our Privacy Policy for additional information.